This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.
4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates
by Ekta Bagri
Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.
Incyte (INCY) Q4 Earnings Miss, Sales Beat on Jakafi, Royalties
by Zacks Equity Research
Incyte's (INCY) earnings miss, but revenues surpass estimates in the fourth quarter on higher royalty revenues and increased Jakafi sales.
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 157%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Vir Biotechnology, Inc. (VIR) points to a 156.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.
Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease
by Zacks Equity Research
Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.
Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat
by Zacks Equity Research
Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Stock Dives on Public Offering of Common Stock
by Zacks Equity Research
Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.
Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
by Zacks Equity Research
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
by Zacks Equity Research
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis
by Zacks Equity Research
Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.
Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA
by Zacks Equity Research
Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down
by Zacks Equity Research
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline
by Zacks Equity Research
Arena Pharmaceuticals' (ARNA) potential acquisition by Pfizer to enable it to advance the development of its pipeline, especially the company's lead candidate, etrasimod, for ulcerative colitis.
Glaxo (GSK), Vir Seek EUA for Intramuscular Sotrovimab in US
by Zacks Equity Research
Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.
Bausch (BHC) Eye Care Business Files for IPO in the US & Canada
by Zacks Equity Research
Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.
Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study
by Zacks Equity Research
Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.
IMV Doses First Patient in the Mid-Stage Study With Keytruda
by Zacks Equity Research
IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda
Vir Biotechnology, Inc. (VIR) Soars 15.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Vir Biotechnology, Inc. (VIR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Vir Biotechnology, Inc. (VIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.